Comparison
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 vs 17p11 2 Microduplication Syndrome C2931246
Clinical comparison between 3 Beta Hydroxysteroid Dehydrogenase Deficiency and 17p11 2 Microduplication Syndrome for differential diagnosis and treatment planning.
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
A rare genetic disorder affecting adrenal hormone production. It can cause ambiguous genitalia, salt-wasting crises, and hormonal imbalances. Treatment requires hormone replacement therapy and careful monitoring.
17p11 2 Microduplication Syndrome C2931246
A chromosomal condition involving duplication on chromosome 17, related to Potocki-Lupski syndrome. Features often include developmental delays, learning challenges, and distinctive facial features.
6 comparison axes
Onset
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
0-null
17p11 2 Microduplication Syndrome C2931246
0-null
Onset patterns differ
Severity
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
severe
17p11 2 Microduplication Syndrome C2931246
moderate
Different severity levels
Chronic
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
Chronic
17p11 2 Microduplication Syndrome C2931246
Chronic
Differing course
Communicable
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
No
17p11 2 Microduplication Syndrome C2931246
No
Different transmission
Body System
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
endocrine
17p11 2 Microduplication Syndrome C2931246
congenital
Same/different system
Category
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
endocrine
17p11 2 Microduplication Syndrome C2931246
genetic
Different category
Bottom line
3-beta-hydroxysteroid-dehydrogenase-deficiency-C0342471 and 17p11-2-microduplication-syndrome-C2931246 differ in severity, etiology
Key differentiating points
Findings that most reliably separate the two conditions at the bedside or in the workup.
| Feature | 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 | 17p11 2 Microduplication Syndrome C2931246 | Discriminating power |
|---|---|---|---|
| Salt-wasting or adrenal crisis | May occur, especially in infancy, with vomiting, dehydration, or shock. | Not a typical feature of the chromosomal syndrome. | High |
| Genital development | Ambiguous or atypical genitalia may occur from disordered steroidogenesis. | Genital ambiguity is not a characteristic feature. | High |
| Development and learning | Not the defining presentation, though illness may affect development. | Developmental delay, learning difficulty, and sometimes autism features are common. | Moderate |
When to favor each condition
Choose 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 when
Infant with suspected adrenal insufficiency
Salt-wasting and abnormal steroid precursors point toward an adrenal enzyme disorder.
High
Atypical genitalia with hormonal imbalance
Disordered adrenal and gonadal steroid production fits this diagnosis better.
Moderate
Abnormal steroid profile needing specialist review
Endocrine testing, not appearance alone, supports enzyme deficiency.
High
Choose 17p11 2 Microduplication Syndrome C2931246 when
Developmental delay with congenital features
A chromosomal microarray can identify 17p11.2 duplication.
High
Learning difficulties and distinctive facial features
This pattern is more consistent with Potocki-Lupski-related duplication.
Moderate
Family history suggesting chromosomal rearrangement
Genetic counseling and chromosomal testing are appropriate.
Moderate
How key tests differ
| Test | 3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471 | 17p11 2 Microduplication Syndrome C2931246 | Interpretation |
|---|---|---|---|
| Serum electrolytes and adrenal steroids | May show salt loss and abnormal steroid precursors; exact cutoffs are not stated here. | No characteristic adrenal steroid abnormality is expected. | Abnormal results suggest endocrine disease but require specialist confirmation. |
| Chromosomal microarray | Does not diagnose this enzyme deficiency. | May detect a 17p11.2 microduplication. | A positive result supports the chromosomal condition, not adrenal enzyme deficiency. |
| HSD3B2 or targeted endocrine genetic testing | May identify causative variants when clinically indicated. | Not the primary test for 17p11.2 duplication. | Test choice should follow phenotype and clinician judgment. |
Prognosis comparison
3 Beta Hydroxysteroid Dehydrogenase Deficiency C0342471
- Outcome
- Chronic condition; outcome depends on early recognition, crisis prevention, and endocrine care. Exact mortality is not established here.
- Factors
- Salt-wasting severity, treatment adherence, and associated illness.
17p11 2 Microduplication Syndrome C2931246
- Outcome
- Generally chronic neurodevelopmental condition with variable learning and developmental needs.
- Factors
- Duplication extent, associated anomalies, therapies, and family support.
Time frame: Lifelong for both, with infancy often critical for the enzyme disorder.
Prognosis should be individualized; sparse source data do not support exact predictions.
Complications comparison
| Complication | Presentation |
|---|---|
| Adrenal crisis | A recognized risk during illness or salt loss. Not characteristic. Urgent care is needed for suspected crisis; this comparison gives no treatment doses. |
| Neurodevelopmental impairment | Not defining, although severe illness may contribute. Developmental and learning challenges are central concerns. Support needs vary and should be individually assessed. |
| Reproductive or pubertal effects | Hormonal imbalance may affect genital development or puberty. Not a defining endocrine complication. Endocrine follow-up is individualized; outcomes are not uniform. |
Patient education highlights
- HighDifferent causes
One is an adrenal steroid enzyme disorder; the other is a chromosome 17 duplication.
- HighEmergency symptoms
Vomiting, dehydration, lethargy, or shock in the enzyme disorder need urgent medical care.
- MediumSupport planning
The duplication syndrome often needs developmental, educational, and genetic-counseling support.